- Kiniksa Pharmaceuticals press release (NASDAQ:KNSA): Q1 GAAP EPS of -$0.18.
- Revenue of $48.3M (+50.0% Y/Y).
- Net loss for the first quarter of 2023 was $12.3 million, compared to a net loss of $25.2 million for the first quarter of 2022.
- As of March 31, 2023, Kiniksa had $187.5 million of cash, cash equivalents, and short-term investments and no debt.
- Financial Guidance
- Kiniksa now expects ARCALYST net product revenue for the full-year 2023 of between $200 million and $215 million vs $220.75M Consensus
- Kiniksa now expects that its cash and cash equivalents will fund its current operating plan into at least 2026.